<DOC>
	<DOCNO>NCT02515630</DOCNO>
	<brief_summary>This study evaluate transfusion independence response rate transfusion-dependent adult myelofibrosis treatment momelotinib ( MMB ) .</brief_summary>
	<brief_title>Momelotinib Transfusion-Dependent Adults With Primary Myelofibrosis ( PMF ) Post-polycythemia Vera Post-essential Thrombocythemia Myelofibrosis ( Post-PV/ET MF )</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Key Diagnosis PMF Post PV/ETMF Requires myelofibrosis therapy , opinion investigator High risk OR intermediate2 risk define dynamic international prognostic scoring system ( DIPSS ) OR intermediate1 risk define DIPSS associate symptomatic splenomegaly and/or hepatomegaly Transfusion dependent baseline , define ≥ 4 U red blood cell ( RBC ) transfusion 8 week prior first dose MMB Acceptable organ function evidence follow : Platelet Count ≥ 50 x 10^9/L Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) ≤ 3 x upper limit normal ( ULN ) AST ALT ≤ 5 x ULN liver involve disease process judge investigator Serum creatinine ≤ 2.0 mg/dL calculate creatinine clearance ≥ 60 mL/min Direct bilirubin ≤ 2.0 x ULN Life expectancy &gt; 24 week Males female childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception Lactating female must agree discontinue nurse MMB administration Able understand willing sign inform consent form Key Prior splenectomy Splenic irradiation within 3 month prior first dose MMB Prior treatment MMB Known positive status human immunodeficiency virus ( HIV ) Chronic active acute viral hepatitis A , B , C infection ( test require hepatitis B C ) , hepatitis B C carrier Use strong cytochrome P450 3A4 ( CYP3A4 ) inducer within 2 week prior first dose MMB Uncontrolled intercurrent illness per protocol Treatment Janus kinase ( JAK ) inhibitor within 21 day plan first dose MMB Presence peripheral neuropathy ≥ Common Terminology Criteria Adverse Events ( CTCAE ) Grade 2 Unwilling unable undergo MRI per requirement study protocol Unwilling consent genomics sample Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>